1 – 100 of 110
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial
(
- Contribution to journal › Article
- 2023
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
2023) In Leukemia and Lymphoma(
- Contribution to journal › Letter
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
2023) In Annals of Oncology(
- Contribution to journal › Article
-
Mark
Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma
(
- Contribution to journal › Article
-
Mark
Secondary malignancies among mantle cell lymphoma patients
(
- Contribution to journal › Article
- 2022
-
Mark
Advances in immune therapies in hematological malignancies
(
- Contribution to journal › Scientific review
-
Mark
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017
(
- Contribution to journal › Letter
-
Mark
The EHA Research Roadmap: Malignant Lymphoid Diseases
(
- Contribution to journal › Article
-
Mark
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma : The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience
(
- Contribution to journal › Article
-
Mark
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Impact of comorbidity in older patients with peripheral T-cell lymphoma : an international retrospective analysis of 891 patients
(
- Contribution to journal › Article
-
Mark
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
(
- Contribution to journal › Letter
-
Mark
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma : a study of younger patients from the MCL2 and MCL3 clinical trials
(
- Contribution to journal › Article
-
Mark
Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission
(
- Contribution to journal › Article
-
Mark
Tackling Mantle Cell Lymphoma in Europe
(
- Contribution to journal › Article
- 2021
-
Mark
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
(
- Contribution to journal › Article
-
Mark
Association between anthropometry and lifestyle factors and risk of B-cell lymphoma : An exposome-wide analysis
(
- Contribution to journal › Article
-
Mark
Newly diagnosed and relapsed follicular lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2021) In Annals of oncology : official journal of the European Society for Medical Oncology 32(3). p.298-308(
- Contribution to journal › Article
-
Mark
Detecting deviations from the efficacy and safety results of single-arm trials using real-world data : The case of a CAR-T cell therapy in B-cell lymphoma
2021) In Pharmacoepidemiology and Drug Safety(
- Contribution to journal › Article
-
Mark
Detailed Long-Term Follow-Up of Patients Who Relapsed after the Nordic Mantle Cell Lymphoma Trials : MCL2 and MCL3
(
- Contribution to journal › Article
-
Mark
EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma : Recommendations for the Second Phase of the COVID-19 Pandemic
(
- Contribution to journal › Scientific review
-
Mark
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
(
- Contribution to journal › Article
-
Mark
Clinical characteristics and histopathological patterns of hodgkin lymphoma and treatment outcomes at a tertiary cancer center in ethiopia
(
- Contribution to journal › Article
-
Mark
Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival
(
- Contribution to journal › Article
-
Mark
Myocardial infarction in diffuse large B-cell lymphoma patients – a population-based matched cohort study
(
- Contribution to journal › Article
-
Mark
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets
(
- Contribution to journal › Article
- 2020
-
Mark
Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition
(
- Contribution to journal › Article
-
Mark
Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women
(
- Contribution to journal › Article
-
Mark
An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement
(
- Contribution to journal › Article
-
Mark
Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk
(
- Contribution to journal › Article
-
Mark
Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study
(
- Contribution to journal › Article
-
Mark
Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
- 2019
-
Mark
Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition
(
- Contribution to journal › Article
-
Mark
Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition
(
- Contribution to journal › Article
-
Mark
Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study
(
- Contribution to journal › Article
-
Mark
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma : A Nordic Lymphoma Epidemiology Group Study
(
- Contribution to journal › Article
-
Mark
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
(
- Contribution to journal › Article
-
Mark
Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?
(
- Contribution to journal › Article
- 2018
-
Mark
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
(
- Contribution to journal › Letter
-
Mark
Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
(
- Contribution to journal › Article
-
Mark
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
(
- Contribution to journal › Article
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
(
- Contribution to journal › Article
-
Mark
Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma : A critical assessment of the R-IPI, IPI, and NCCN-IPI
(
- Contribution to journal › Article
-
Mark
Ibrutinib versus temsirolimus : 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
(
- Contribution to journal › Article
-
Mark
Impact of comorbidity on survival in peripheral T-cell lymphomas : A Swedish Lymphoma Registry study
(
- Contribution to journal › Article
-
Mark
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
(
- Contribution to journal › Article
- 2017
-
Mark
Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.
(
- Contribution to journal › Article
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
(
- Contribution to journal › Article
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter
-
Mark
International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma
(
- Contribution to journal › Article
-
Mark
Outcome of peripheral T-cell lymphoma in first complete remission : a Danish-Swedish population-based study
(
- Contribution to journal › Article
-
Mark
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
(
- Contribution to journal › Article
-
Mark
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
(
- Contribution to journal › Article
- 2016
-
Mark
Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.
(
- Contribution to journal › Article
-
Mark
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma : a Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4
(
- Contribution to journal › Article
-
Mark
Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma : a Swedish Lymphoma Registry study
(
- Contribution to journal › Article
-
Mark
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement : An international multicenter collaboration
(
- Contribution to journal › Article
-
Mark
No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.
2016) In British Journal of Haematology(
- Contribution to journal › Article
- 2015
-
Mark
Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment
(
- Contribution to journal › Article
-
Mark
Emerging role of SOX11 in mantle cell lymphoma
(
- Contribution to journal › Scientific review
-
Mark
Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study
(
- Contribution to journal › Article
-
Mark
The impact of age on survival of diffuse large B-cell lymphoma - a population-based study
(
- Contribution to journal › Article
-
Mark
Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer.
(
- Contribution to journal › Article
-
Mark
Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.
(
- Contribution to journal › Article
-
Mark
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.
(
- Contribution to journal › Article
-
Mark
Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study
(
- Contribution to journal › Article
-
Mark
Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
(
- Contribution to journal › Article
-
Mark
Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.
2015) In Hematological Oncology(
- Contribution to journal › Article
-
Mark
Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
2015) In European Journal of Haematology(
- Contribution to journal › Article
- 2014
-
Mark
Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry
(
- Contribution to journal › Article
-
Mark
Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma.
(
- Contribution to journal › Article
-
Mark
High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
(
- Contribution to journal › Letter
-
Mark
Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study
(
- Contribution to journal › Article
-
Mark
Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays.
(
- Contribution to journal › Article
- 2013
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
(
- Contribution to journal › Article
- 2012
-
Mark
Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Expanded clinical and experimental use of SOX11-using a monoclonal antibody
(
- Contribution to journal › Article
- 2011
-
Mark
Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.
(
- Contribution to journal › Article
-
Mark
Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.
(
- Contribution to journal › Article
-
Mark
Nordic MCL2 Trial of 1St-Line Intensive Immunochemotherapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: Still Encouraging Results After Median 5½ Years Observation Time
2011) Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem In Biology of Blood and Marrow Transplantation 17(2). p.196-196(
- Contribution to journal › Published meeting abstract
-
Mark
Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group.
(
- Contribution to journal › Article
-
Mark
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
(
- Contribution to journal › Article
- 2010
-
Mark
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
(
- Contribution to journal › Article
-
Mark
SOX11 expression correlates to promoter methylatuion and regulates tumor growth in hematopoietic malignancies
(
- Contribution to journal › Article
-
Mark
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
(
- Contribution to journal › Article
- 2009
-
Mark
Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA
2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology In Journal of Clinical Oncology 27(15).(
- Contribution to journal › Published meeting abstract
-
Mark
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
(
- Contribution to journal › Article
-
Mark
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma.
(
- Contribution to journal › Article
- 2008
-
Mark
Transformed diffuse large B cell lymphomas differ from follicular lymphomas in both gene and protein expression
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.111-111(
- Contribution to journal › Published meeting abstract
-
Mark
BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.142-142(
- Contribution to journal › Published meeting abstract
-
Mark
Burkitt's lymphoma: Comparison of 2 nationwide population-based lymphoma registries
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.131-131(
- Contribution to journal › Published meeting abstract
-
Mark
Sox11, a non-B cell lineage transcription factor, is overexpressed in mantle cell lymphoma
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.172-173(
- Contribution to journal › Published meeting abstract
-
Mark
B cell lymphomas express CX(3)CR1 a non-B cell lineage adhesion molecule.
(
- Contribution to journal › Article
- 2007
-
Mark
Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN
(
- Contribution to journal › Article
-
Mark
CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma.
(
- Contribution to journal › Article